Single-Agent Tislelizumab, an Anti-PD-1 Antibody: Results from a Phase 1 Expansion Cohort in NSCLC Patients

被引：1
|
作者：
Barlow, P. [1 ]
Jameson, M. [2 ,3 ]
Lin, C. [4 ]
Wu, J. [5 ]
Pirzkall, A. [5 ]
Lee, J. [6 ]
机构：
[1] Auckland City Hosp, Auckland, New Zealand
[2] Waikato Hosp, Reg Canc Ctr, Hamilton, New Zealand
[3] Univ Auckland, Waikato Clin Campus, Hamilton, New Zealand
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Beigene Usa Inc, San Mateo, CA USA
[6] Seoul Natl Univ, Bundang Hosp, Seongnam Si, Gyeonggi Do, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
tislelizumab; NSCLC; Anti-PD-1;
D O I：
10.1016/j.jtho.2019.08.1538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-33
引用
收藏
页码：S721 / S721
页数：1
相关论文
共 50 条
  • [1] Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
    Desai, Jayesh
    Deva, Sanjeev
    Lee, Jong Seok
    Lin, Chia-Chi
    Yen, Chia-Jui
    Chao, Yee
    Keam, Bhumsuk
    Jameson, Michael
    Hou, Ming-Mo
    Kang, Yoon-Koo
    Markman, Ben
    Lu, Chang-Hsien
    Rau, Kun-Ming
    Lee, Kyung-Hun
    Horvath, Lisa
    Friedlander, Michael
    Hill, Andrew
    Sandhu, Shahneen
    Barlow, Paula
    Wu, Chi-Yuan
    Zhang, Yun
    Liang, Liang
    Wu, John
    Paton, Virginia
    Millward, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [2] Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study
    Sandhu, S.
    Hill, A.
    Gan, H.
    Friedlander, M.
    Voskoboynik, M.
    Barlow, P.
    Townsend, A.
    Song, J.
    Zhang, Y.
    Liang, L.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 28 - 28
  • [3] Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
    Dimitriou, F.
    Namikawa, K.
    Reijers, I. L. M.
    Buchbinder, E., I
    Soon, J. A.
    Zaremba, A.
    Teterycz, P.
    Mooradian, M. J.
    Armstrong, E.
    Nakamura, Y.
    Vitale, M. G.
    Tran, L. E.
    Bai, X.
    Allayous, C.
    Provent-Roy, S.
    Indini, A.
    Bhave, P.
    Farid, M.
    Kahler, K. C.
    Mehmi, I
    Atkinson, V
    Klein, O.
    Stonesifer, C. J.
    Zaman, F.
    Haydon, A.
    Carvajal, R. D.
    Hamid, O.
    Dummer, R.
    Hauschild, A.
    Carlino, M. S.
    Mandala, M.
    Robert, C.
    Lebbe, C.
    Guo, J.
    Johnson, D. B.
    Ascierto, P. A.
    Shoushtari, A. N.
    Sullivan, R. J.
    Cybulska-Stopa, B.
    Rutkowski, P.
    Zimmer, L.
    Sandhu, S.
    Blank, C. U.
    Lo, S. N.
    Menzies, A. M.
    Long, G., V
    ANNALS OF ONCOLOGY, 2022, 33 (09) : 968 - 980
  • [4] Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC).
    Wang, Siyang
    Huang, Xiaoming
    Bai, Yu-Xian
    Yuan, Ying
    Li, Jian
    Wang, Zuobai
    Wei, Chenlu
    Li, Xin
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (12) : 1355 - 1363
  • [7] Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC
    Huo, Yachang
    Wang, Dan
    Yang, Shuangning
    Xu, Yujie
    Qin, Guohui
    Zhao, Chenhui
    Lei, Qingyang
    Zhao, Qitai
    Liu, Yaqing
    Guo, Kaiyuan
    Ouyang, Songyun
    Sun, Ting
    Wang, Hongmin
    Fan, Feifei
    Han, Na
    Liu, Hong
    Chen, Hongjie
    Miao, Lijun
    Liu, Li
    Duan, Yuqing
    Lv, Wei
    Liu, Lihua
    Zhang, Zhixin
    Cang, Shundong
    Wang, Liping
    Zhang, Yi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (12)
  • [8] The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab
    Feng, Yingcai
    Hong, Yuan
    Sun, Hanzi
    Zhang, Bo
    Wu, Hongfu
    Li, Kang
    Liu, Xuesong
    Liu, Ye
    CANCER RESEARCH, 2019, 79 (13)
  • [9] Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts
    Moreno, V.
    Gil-Martin, M.
    Johnson, M.
    Aljumaily, R.
    Lopez-Criado, M. P.
    Northfelt, D.
    Crittenden, M.
    Jabbour, S.
    Rosen, L.
    Calvo, E.
    Papadopoulos, K.
    Garrido, P.
    Hervas Moron, A.
    Rietschel, P.
    Mohan, K.
    Li, J.
    Stankevich, E.
    Feng, M.
    Lowy, I.
    Fury, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S366 - S366
  • [10] A PHASE I DOSE ESCALATION AND EXPANSION STUDY OF INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PATIENTS WITH ADVANCED SOLID TUMORS
    Eigentler, Thomas
    Heinzerling, Lucie
    Krauss, Juergen
    Weishaupt, Carsten
    Mohr, Peter
    Ochsenreither, Sebastian
    Terheyden, Patrick
    Martin-Liberal, Juan
    Oliva, Marc
    Lebbe, Celeste
    Fluck, Michael
    Brossart, Peter
    Trigo Perez, Jose Manuel
    Bauernfeind, Franz-Georg
    Kays, Sarah-Katharina
    Seibel, Tobias
    Schoenborn-Kellenberger, Oliver
    Stosnach, Claudia
    Daehling, Angelika
    Schmitt-Bormann, Beate
    Gnad-Vogt, Ulrike
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A478 - A479
12345